Пузырчатка: актуальные звенья патогенеза и терапии

1. Общероссийская общественная организация «Российское общество дерматовенерологов и косметологов». Клинические рекомендации. Пузырчатка. 2020.

2. Huda S., Chau B., Chen C., et al. Caspase Inhibition as a Possible Therapeutic Strategy for Pemphigus Vulgaris: A Systematic Review of CurrentEvidence. Biology (Basel). 2022;11(2):314. doi: 10.3390/ biology11020314/

3. Completesequenceandgenemapofahumanmajor histocompatibility complex. The MHC sequencing consortium. Nature. 1999;401(6756):921–23. doi: 10.1038/44853.

4. Brochado M.J., Nascimento D.F., Campos W., et al. Differential HLA class I and class II associations in pemphigus foliaceus and pemphigus vulgaris patients from a prevalent Southeastern Brazilian region. J Autoimmun. 2016;72:19–24. doi: 10.1016/j.jaut.2016.04.007.

5. Yan L., Wang J.M., Zeng К. Association Between HLA-DRB1 polymorphisms and pemphigus vulgaris: а meta-analysis. Br J Dermatol. 2012;167(4):768–77. doi: 10.1111/j.1365-2133.2012.11040.x.

6. Egami S., Yamagami J., Amagai M. Autoimmune bullous skin diseases, pemphigus and pemphigoid. J Allergy Clin Immunol. 2020;145(4):1031–47. doi: 10.1016/j.jaci.2020.02.013.

7. Vodo D., Sarig O., Sprecher E. The Genetics of Pemphigus Vulgaris. Front Med (Lausanne). 2018;5:226. doi: 10.3389/fmed.2018.00226.

8. Zhang S.Y., Zhou X.Y., Zhou X.L., et al. Subtype-specific inherited predisposition to pemphigus in the Chinese population. Br J Dermatol. 2019;180(4):828–35. doi: 10.1111/ bjd.17191.

9. Assaf S., Malki L., Mayer T., et al. ST18 affects cell-cell adhesion in pemphigus vulgaris in a tumour necrosis factor-α-dependent fashion. Br J Dermatol. 202;184(6):1153–60. doi: 10.1111/ bjd.19679.

10. Etesami I., Seirafi H., Ghandi N. et al. The association between ST18 gene polymorphism and severe pemphigus disease among Iranian population. Exp Dermatol. 2018;27(12):1395–98. doi: 10.1111/exd.13778.

11. Sarig O., Bercovici S., Zoller L., et al. Population-specific association between a polymorphic variant in ST18, encoding a pro-apoptotic molecule, and pemphigus vulgaris. J Invest Dermatol. 2012;132(7):1798–805. doi: 10.1038/ jid.2012.46.

12. Yue Z., Fu X., Chen M., et al. Lack of association between the single nucleotide polymorphism of ST18 and pemphigus in Chinese population. J Dermatol. 2014;41(4):353–54. doi: 10.1111/1346-8138.12363.

13. Vodo D., et al. Identification of а functional risk variant for pemphigus vulgaris in the ST18 gene. PLoS Genet. 2016;12:e1006008. doi: 10.1371/ journal.pgen.1006008.

14. Radeva M.Y., Walter E., Stach R.A., et al. ST18 Enhances PV-IgG-Induced Loss of Keratinocyte Cohesion in Parallel to Increased ERK Activation. Front Immunol. 2019;10:770. doi: 10.3389/ fimmu.2019.00770.

15. Martel P., Loiseau P., Joly P., et al. Paraneoplastic pemphigus is associated with the DRB1*03 allele. J Autoimmun. 2003;20(1):91–5. doi: 10.1016/s0896-8411(02)00092-6.

16. Kasperkiewicz M., Ellebrecht C.T., Takahashi H., et al. Pemphigus. Nat Rev Dis Primers. 2017;3:17026. doi: 10.1038/nrdp.2017.26.

17. Liu Q., Bu D.F., Li D., Zhu X.J. Genotyping of HLA-I and HLA-II alleles in Chinese patients with paraneoplastic pemphigus. Br J Dermatol. 2008;158(3):587–91. doi: 10.1111/j.1365- 2133.2007.08361.x.

18. Ghaedi F., Etesami I., Aryanian Z., Kalantari Y., et al. Drug-induced pemphigus: A systematic review of 170 patients. Int Immunopharmacol. 2021;92:107299. doi: 10.1016/j. intimp.2020.107299.

19. Koutlas I.G., Camara R., Argyris P.P., et al. Development of pemphigus vulgaris after the second dose of the mRNA-1273 SARS-Cov-2 vaccine. Oral Dis. 2021 Nov 26. doi: 10.1111/ odi.14089.

20. Kitajima Y. 150(th) anniversary series: Desmosomes and autoimmune disease, perspective of dynamic desmosome remodeling and its impairments in pemphigus. Cell Commun Adhes. 2014;21(6):269–80. doi: 10.3109/15419061.2014.943397.

21. Price A.J., Cost A.L., Ungewiβ H., et al. Mechanical loading of desmosomes depends on the magnitude and orientation of external stress. Nat Commun. 2018;9(1):5284. doi: 10.1038/ s41467-018-07523-0.

22. Schmidt E., Kasperkiewicz M., Joly P. Pemphigus. Lancet. 2019;394(10201):882–94. doi: 10.1016/S0140-6736(19)31778-7.

23. Hanakawa Y., Amagai M., Shirakata Y., et al. Differential effects of desmoglein 1 and desmoglein 3 on desmosome formation. J Invest Dermatol. 2002;119(6):1231–36. doi: 10.1046/j.1523-1747.2002.19648.x.

24. Amagai M., Stanley J.R. Desmoglein as a Target in Skin Disease and beyond. J. Invest. Dermatol. 2012;132:776–84. 10.1038/jid.2011.390. doi: 10.1038/jid.2011.390.

25. Anhalt G.J., Labib R.S., Voorhees J.J., et al. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med. 1982;306(20):1189–96. doi: 10.1056/NEJM198205203062001.

26. Amagai М., Nishikawa Т., Nousari Н.С., et al. AntiBodies against desmoglein 3 (Pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest. 1998;102(4):775–82. doi: 10.1172/JCI3647.

27. Okano M., Takijiri C., Aoki T., et al. Pemphigus vulgaris associated with pregnancy. A case report from Japan. Acta Derm Venereol. 1990;70(6):517–19.

28. Махнева Н.В., Давиденко Е.Б., Зайденов В.А., Белецкая Л.В. Участие иммуноглобулина G и его субклассов в развитии и течении аутоиммунной пузырчатки. Фундаментальные исследования. 2013;11:79–84.

29. Yang M., Wu H., Zhao M., et al. The pathogenesis of bullous skin diseases. J Transl Autoimmun. 2019;2:100014. doi: 10.1016/j. jtauto.2019.100014.

30. Maruta C.W., Miyamoto D., Aoki V., et al. Paraneoplastic pemphigus: a clinical, laboratorial, and therapeutic overview. An Bras Dermatol. 2019;94(4):388–98. doi: 10.1590/abd1806- 4841.20199165.

31. Kappius R.H., Ufkes N.A., Thiers B.H. Paraneoplastic Pemphigus. 2021 Sep 7. In: StatPearls

32. Mao X., Sano Y., Park J.M., Payne A.S. p38 MAPK activation is downstream of the loss of intercellular adhesion in pemphigus vulgaris. J Biol Chem. 2011;286(2):1283–91. doi: 10.1074/jbc. M110.172874.

33. Jolly P.S., Berkowitz P., Bektas M., et al. p38MAPK signaling and desmoglein-3 internalization are linked events in pemphigus acantholysis. J Biol Chem. 2010;285(12):8936–41. doi: 10.1074/ jbc.M109.087999.

34. Hammers С.М., Stanley J.R. Mechanisms of Disease: pemphigus and Bullous Pemphigoid. Ann Rev Pathol. 2016;11:175–97. doi: 10.1146/ annurev-pathol-012615-044313.

35. Didona D., Maglie R., Eming R., Hertl М. Pemphigus: Current and Future Therapeutic Strategies. Front Immunol. 2019;10:1418. doi: 10.3389/fimmu.2019.

36. Yuan H., Zhou S., Liu Z., et al. Pivotal Role of Lesional and Perilesional T/B Lymphocytes in Pemphigus Pathogenesis. J Invest Dermatol. 2017;137(11):2362–70. doi: 10.1016/j. jid.2017.05.032.

37. Hammers С.М., Chen J., Lin С. et al. Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years. J Invest Dermatol. 2015;135(3):742–49. doi: 10.1038/ jid.2014.291.

38. Reich К., Brinck U., Letschert М., et al. Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus. Br J Dermatol. 1999;141(4):739– 46. doi: 10.1046/j.1365-2133.1999.03123.x.

39. Paolino G., Didona D., Magliulo G., et al. Paraneoplastic Pemphigus: Insight into theAutoimmune Pathogenesis, Clinical Features and Therapy. Int J Моl Sci. 2017;18(12):2532. doi: 10.3390/ijms18122532.

40. Bystryn J.C., Steinman N.M. The adjuvant therapy of pemphigus. An update. Arch Dermatol. 1996;132(2):203–12.

41. Murrell D.F., Pena S., Joly P., et al. Diagnosis and management of pemphigus: Recommendations of an international panel of experts. J Am Acad Dermatol. 2020;82(3):575–85.e1. doi: 10.1016/j.jaad.2018.02.021.

42. Kridin К. Emerging treatment options for the management of pemphigus vulgaris. Ther Clin Risk Manag. 2018;14:757–78. doi: 10.2147/ TCRM.S142471.

43. Joly P., Horvath B., Patsatsi A., et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900–13. doi: 10.1111/jdv.16752.

44. Mouquet H., Musette P., Gougeon M.L., et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol. 2008;128(12):2859–69. doi: 10.1038/jid.2008.178.

45. Velmurugan R., Challa D.K., Ram S., et al. Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells. Mol Cancer Ther. 2016;15(8):1879–89. doi: 10.1158/1535-7163.MCT-15-0335.

46. Colliou N., Picard D., Caillot F., et al. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med. 2013;5(175):175ra30. doi: 10.1126/ scitranslmed.3005166.

47. Balighi K., Daneshpazhooh M., Khezri S., et al. Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial. Int J Dermatol. 2013;52(7):862–67. doi: 10.1111/j.1365- 4632.2012.5847.x.

48. Nooka A., Shenoy P.J., Sinha R., et al. Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature. Clin Lymph Myel Leuk. 2011;11(5):379–84. doi: 10.1016/j. clml.2011.04.005

49. Perifani V., Dalamaga M., Theodoropoulos K. et al. Real world evidence: Patients with refractory pemphigus treated with Rituximab. Metab Open. 2021;12:100142. doi: 10.1016/j. metop.2021.100142.

50. Maltzman J.S., Koretzky G.A. Azathioprine: old drug, new actions. J Clin Invest. 2003;111(8):1122–24. doi: 10.1172/ JCI18384.

51. Olejarz W., Bryk D., Zapolska-Downar D. Mycophenolate mofetil – a new atheropreventive drug? Acta Pol. Pharm. 2014;71(3):353–61.

52. Baum S., Greenberger S., Samuelov L., et al. Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris. Eur J Dermatol. 2012;22(1):83–7. doi: 10.1684/ ejd.2011.1611.

53. Olszewska M., Kolacinska-Strasz Z., Sulej J., et al. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. Am J Clin Dermatol. 2007;8(2):85–92. doi: 10.2165/00128071-200708020-00004.

54. Dourmishev L.A., Guleva D.V., Miteva L.G. Intravenous Immunoglobulins: Mode of Action and Indications in Autoimmune and Inflammatory Dermatoses. Int J Inflam. 2016;2016:3523057. doi: 10.1155/2016/3523057.

55. Chaigne B., Mouthon L. Mechanisms of action of intravenous immunoglobulin. Transfus. Apher. Sci. 2017;56(1):45–9. doi: 10.1016/j. transci.2016.12.017.

56. Sinha A.A., Hoffman M.B., Janicke E.C.Pemphigus vulgaris: approach to treatment. Eur J Dermatol. 2015;25(2):103–13. doi: 10.1684/ ejd.2014.2483.

57. Cang S., Mukhi N., Wang K., Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol. 2012;5:64. doi: 10.1186/1756- 8722-5-64.

58. Rapp M., Pentland A., Richardson C. Successful Treatment of Pemphigus Vulgaris With Ofatumumab. J Drugs Dermatol. 2018;17(12):1338–39.

59. Klufas D.M., Amerson E., Twu O., et al. Refractory pemphigus vulgaris successfully treated with ofatumumab. JAAD. Case Rep. 2020;6(8):734– 6. doi: 10.1016/j.jdcr.2020.05.034.

60. Li N., Zhao M., Hilario-Vargas J., et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest. 2005;115(12):3440–50. doi: 10.1172/ JCI24394.

61. Izumi K., Bieber K., Ludwig R.J. Current Clinical Trials in Pemphigus and Pemphigoid. Front Immunol. 2019;10:978. doi: 10.3389/ fimmu.2019.00978.

62. Werth V.P., Culton D.A., Concha J.S.S., et al. Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus. J Invest Dermatol. 2021;141(12):2858–65.e4. doi: 10.1016/j.jid.2021.04.031.

63. Nelson C.A., Tomayko M.M. Targeting the FcRn: A Novel Approach to the Treatment of Pemphigus. J Invest Dermatol. 2021;141(12):2777–80. doi: 10.1016/j.jid.2021.06.035.

64. Ellebrecht C.T., Bhoj V.G., Nace A., et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science. 2016;353(6295):179–84. doi: 10.1126/ science.aaf6756.

65. Nelson C.A., Tomayko M.M. Targeting the FcRn: A Novel Approach to the Treatment of Pemphigus. J Invest Dermatol. 2021;141(12):2777–80. doi: 10.1016/j.jid.2021.06.035.

66. Tavakolpour S. Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus. Dermatol Ther. 2018;31(5):e12696. doi: 10.1111/dth.12696.